1 Min Read
Oct 12 (Reuters) - Cytrx Corp:
* Cytrx Corporation highlights inclusion of aldoxorubicin in pending upcoming clinical trial submissions planned by Licensee Nantcell, Inc. Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.